Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZL0420 是有效且选择性的 BET 溴结构域 4 (BRD4) 抑制剂,对 BRD4 的溴结构域 (BD) 具有纳摩尔结合亲和力。ZL0420 对 BRD4 BD1和 BRD4 BD2 的IC50分别为 27 nM 和 32 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 980 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 3,160 | 现货 | ||
50 mg | ¥ 4,590 | 现货 | ||
100 mg | ¥ 6,430 | 现货 | ||
200 mg | ¥ 8,670 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 916 | 现货 |
产品描述 | ZL0420 is a potent and selective bromodomain-containing protein 4 ( BRD4 ) inhibitor with nanomolar binding affinities to bromodomains (BDs) of BRD4. ZL0420 has IC 50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2. |
体外活性 | ZL0420 is well docked into the acetyl-lysine (KAc) binding pocket of BRD4 that forms key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H 2 O molecule. ZL0420 exhibits submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs) with IC 50 s of 0.49-0.86 μM [1]. |
体内活性 | ZL0420 displays potent efficacy reducing airway inflammation in a mouse model with low toxicity. ZL0420 displays highly potent and almost completely blocks the profound accumulation of neutrophils around the small and medium sized airways induced by poly(I:C) administration [1]. |
动物实验 | Male C57BL6/J mice housed under pathogen-free conditions with food and water ad libitum.?C57BL/6 mice were pre-treated in the absence or presence of the indicated BRD4 inhibitors [10 mg/kg body weight, via the intraperitoneal route] one day prior to poly stimulation.?The next day, animals were given another dose of BRD4 inhibitor immediately followed by intranasal ?administration of phosphate-buffered saline (PBS, 50 μL) or poly (300 μg dissolved in 50 μL PBS).?One day later, the mice were euthanized.?The bronchoalveolar lavage fluid (BALF) and lung tissues of treated mice were collected for further analysis.?Compounds were first dissolved in DMSO and further diluted in 10% hydroxypropyl β-cyclodextrin in PBS to appropriate concentration prior to intraperitoneal administration. |
分子量 | 296.32 |
分子式 | C16H16N4O2 |
CAS No. | 2229039-45-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 59 mg/mL (199.11 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | 84.3683 mL |
5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | 16.8737 mL | |
10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL | 8.4368 mL | |
20 mM | 0.1687 mL | 0.8437 mL | 1.6874 mL | 4.2184 mL | |
50 mM | 0.0675 mL | 0.3375 mL | 0.6749 mL | 1.6874 mL | |
100 mM | 0.0337 mL | 0.1687 mL | 0.3375 mL | 0.8437 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ZL0420 2229039-45-4 Chromatin/Epigenetic Epigenetic Reader Domain ZL 0420 inhibit (E/Z)-ZL0420 BRD4 airway inflammation immune response genes ZL-0420 BET bromodomains Inhibitor inhibitor